Clinical trials: Psoriatic Subjects
Psoriatic Arthritis
Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis
The purpose of the study was to compare the efficacy of 2 different Etanercept regimens for the treatment of skin and joint manifestations of psoriatic arthritis.
- Trial name
- NCT00245960
- Testing
- etanercept
- Where
- 120 sites in Argentina, Australia and 24 more
- Volunteers
- 752 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Psoriatic Arthritis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of tumor necrosis factor alpha-inadequate responders (TNFα-IR)…
- Trial name
- BE COMPLETE (NCT03896581)
- Testing
- Bimekizumab
- Where
- 92 sites in United States, Australia and 9 more
- Volunteers
- 400 people
- Sponsor
- UCB Biopharma SRL
Psoriatic Arthritis
Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time.
- Trial name
- NCT06865105
- Testing
- Lutikizumab, Risankizumab
- Where
- 37 sites in United States, Canada and 4 more
- Volunteers
- 120 people
- Sponsor
- AbbVie
PsA (Psoriatic Arthritis)
A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis
This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. The target population is patients with active psoriatic arthritis. A total of 222 subjects are planned to be included.
- Trial name
- D2570-204 (NCT07315061)
- Testing
- D-2570
- Where
- China
- Volunteers
- 222 people
- Sponsor
- InventisBio Co., Ltd
Autoimmune Diseases
A Study to Evaluate the Safety, Mode of Action and Clinical Efficacy of GSK3050002 in Subjects With Psoriatic Arthritis
Chemokine (C-C motif) ligand 20 (CCL20) is a protein involved in attracting immune cells including subsets of T cells (for example Th17 cells), B cells, natural killer cells and dendritic cells to inflamed tissues in conditions…
- Trial name
- NCT02671188
- Testing
- GSK3050002
- Where
- United Kingdom
- Sponsor
- GlaxoSmithKline
Psoriatic Arthritis
An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis
The purpose of this study is to evaluate the effectiveness and safety of CNTO 1275 (ustekinumab) in patients with psoriatic arthritis.
- Trial name
- NCT00267956
- Testing
- CNTO 1275 63 mg
- Where
- 25 sites in United States, Canada and 3 more
- Volunteers
- 146 people
- Sponsor
- Centocor, Inc.
Psoriatic Arthritis
A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic Arthritis
This is a multicenter, Phase 2, double-blind, placebo-controlled study in subjects with moderately to severely active Psoriatic Arthritis (PsA) who have an inadequate response or are intolerant to conventional disease-modifying…
- Trial name
- EQUATOR (NCT03101670)
- Testing
- filgotinib
- Where
- 25 sites in Belgium, Bulgaria and 5 more
- Volunteers
- 131 people
- Sponsor
- Lakefront Biotherapeutics NV
Psoriatic Arthritis
A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
This is a study to assess the long-term safety, long-term efficacy and tolerability of bimekizumab administered subcutaneously (sc) in adult subjects with psoriatic arthritis (PsA).
- Trial name
- BE VITAL (NCT04009499)
- Testing
- Bimekizumab
- Where
- 138 sites in United States, Australia and 12 more
- Volunteers
- 1,131 people
- Sponsor
- UCB Biopharma SRL
Healthy, Psoriatic Subjects
Randomized, Double-blind, Placebo-controlled Study of RSS0393 Ointment in Healthy and Psoriatic Subjects
Randomized, double-blind, placebo-controlled study of RSS0393 ointment in healthy and psoriatic subjects
- Trial name
- NCT06308393
- Where
- 2 sites in China
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Psoriatic Arthritis
A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX)
This study is a Phase 2 randomized, double-blind, double-dummy, active- and placebo-controlled, parallel-group study designed to assess the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of multiple doses of…
- Trial name
- NCT02349451
- Testing
- adalimumab, ABT-122
- Volunteers
- 240 people
- Sponsor
- AbbVie
Active Psoriatic Arthritis
Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)
The main purpose of study is to assess the dose-response relationship of BMS-986165 (Dose A or Dose B once daily [QD]) at Week 16 in the treatment of participants with active PsA.
- Trial name
- NCT03881059
- Testing
- BMS-986165 Dose A, BMS-986165 Dose B, Ustekinumab
- Where
- 94 sites in United States, Czechia and 7 more
- Volunteers
- 203 people
- Sponsor
- Bristol-Myers Squibb
Systemic Lupus Erythematosus, Arthritic Psoriasis
A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation
The purpose of this study is to evaluate BMS-986165 tablet formulation versus BMS-986165 capsule formulation. This study will also evaluate the effect of a high-fat/ high-calorie meal and increased gastric pH on the BMS-986165…
- Conditions
- Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
- Trial name
- NCT03254784
- Testing
- BMS-986165 Capsule, BMS-986165 Tablet
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Psoriatic Arthritis
Psoriatic Arthritis Study of Izokibep
Izokibep is a potent and selective inhibitor of interleukin (IL)-17A that is being developed for treatment of psoriatic arthritis (PsA). This study will evaluate the efficacy of izokibep in subjects with PsA.
- Trial name
- NCT05623345
- Testing
- Izokibep
- Where
- 71 sites in United States, Bulgaria and 6 more
- Volunteers
- 351 people
- Sponsor
- ACELYRIN Inc.
Arthritis, Psoriatic
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis
The primary purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
- Trial name
- NCT03158285
- Testing
- Guselkumab
- Where
- 138 sites in United States, Bulgaria and 11 more
- Volunteers
- 741 people
- Sponsor
- Janssen Research & Development, LLC
Arthritis, Psoriatic
Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy
Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severely Active Psoriatic Arthritis Subjects with Inadequate Response to Disease Modifying anti-Rheumatic Drug Therapy
- Trial name
- NCT00646178
- Testing
- adalimumab
- Volunteers
- 102 people
- Sponsor
- Abbott
Psoriatic Arthritis
A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis
This is a 52 week Phase 2b study designed to evaluate the efficacy at 16 weeks and to evaluate the safety and efficacy up to 1 year in subjects with active psoriatic arthritis.
- Trial name
- NCT03963401
- Testing
- PF-06700841
- Where
- 48 sites in Australia, Bulgaria and 9 more
- Volunteers
- 219 people
- Sponsor
- Pfizer
Psoriatic Arthritis (PsA)
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).
- Trial name
- KEEPsAKE2 (NCT03671148)
- Testing
- Risankizumab
- Where
- 138 sites in United States, Argentina and 23 more
- Volunteers
- 444 people
- Sponsor
- AbbVie
Inflammation, Psoriasis
First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects
This trial is conducted in the United States of America (USA). The aim of this clinical trial is evaluate the safety and tolerability of anti-IL-20 in patients with psoriasis and to determine the preliminary efficacy in an…
- Trial name
- NCT01261767
- Testing
- anti-IL-20
- Where
- 16 sites in United States
- Volunteers
- 55 people
- Sponsor
- Novo Nordisk A/S
Psoriatic Arthritis
24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis
The purpose of this study is to provide 24 - 52 week efficacy, safety and tolerability data, and up to 3-year efficacy, safety and tolerability data in subjects with active Psoriatic Arthritis despite current or previous…
- Trial name
- NCT01989468
- Testing
- Secukinumab
- Where
- 77 sites in United States, Australia and 11 more
- Volunteers
- 414 people
- Sponsor
- Novartis Pharmaceuticals
Psoriatic Arthritis, Withdrawal
Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis
The rationale for this study is to investigate whether in psoriatic arthritis (PsA) patients in stable remission a reduction or complete discontinuation of immunosuppressive therapy can be achieved in a treat-to-target approach…
- Conditions
- Psoriatic Arthritis, Withdrawal, Reduction
- Trial name
- NCT04610476
- Testing
- Prednisolone, Sulfasalazine, Leflunomide
- Where
- Germany
- Volunteers
- 270 people
- Sponsor
- University of Erlangen-Nürnberg Medical School